Tiziana Life Sciences PLC   | AIM:TILS


KEY POINTS


  1. Cancer deaths rose to 8.2 million worldwide in 2012, an increase of 8% from 2008, with a particularly sharp rise in breast cancer deaths (up 14%) in the same period

  2. There were approximately 522,000 worldwide deaths attributable to breast cancer in 2012.

  3. The breast cancer drug market is predicted to be US$10.4bn in 2019, of which 25% is expected to comprise targeted therapeutics

  4. Metastasis, the spread of tumours around the body, accounts for more than 90% of all cancer related deaths

  5. Cancer is primarily due to uncontrolled cell cycle eventually resulting in transformation of normal cells to rapidly growing cancer cells.

 

Our Technology

We are developing innovative drugs for treatment of cancers and autoimmune diseases. We have potent candidate therapeutics in the clinic for thymic cancer, as well as programmes in breast cancer and autoimmune disease which we anticipate to move into clinical trials in 2016.

THYMIC & LIVER CANCER

ORPHAN DRUG STATUS


We are focusing on a late stage CDK inhibitor, milciclib for thymoma cancer which has orphan drug status. milciclib is currently in late Phase II study for thymoma. This candidate may have potential in other cancer, such as liver carcinoma and breast cancer.


Find out more »

 

BREAST CANCER

INCLUDING TRIPLE NEGATIVE BREAST CANCER


We have acquired a specific inhibitor of Bcl-3 function from Cardiff University capable of inhibiting triple-negative, HER-2-positive and ER-positive breast cancer metastases. We anticipate filing an IND in 2016.




Find out more »


Tiziana Life Sciences has recently acquired IP associated with a small molecule inhibitor of c-Flip (known as OH14). The company is funding early development studies to provide proof-of-principle for this new class of agent in targeting cancer stem cell sub-populations within pre-clinical model systems.


Find out more »

 

AUTOIMMUNE DISEASES

IBD, TYPE I DIABETES & LUPUS


We have acquired foralumab, a fully human anti-CD3 antibody a unique asset for treatment of autoimmune diseases such as inflammatory bowel diseases, type I diabetes and lupus. We anticipate filing an IND in 2016.


Find out more »